Previous close | 2.6500 |
Open | 2.8000 |
Bid | 0.0000 |
Ask | 1.9500 |
Strike | 16.00 |
Expiry date | 2024-08-16 |
Day's range | 2.6500 - 2.8000 |
Contract range | N/A |
Volume | |
Open interest | 35 |
Novartis (NVS) reports phase III data that confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria.
Gilead Sciences, Inc.'s (GILD) confirmatory TROPiCS-04 study on Trodelvy in locally advanced or metastatic urothelial cancer fails to achieve its primary endpoint.
Ultragenyx (RARE) reports meeting primary and secondary endpoints in the late-stage study of its investigational gene therapy, DTX401, to treat glycogen storage disease type Ia.